Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35074072

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Mar
First author
Wang ML

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Mar;23(3):321-322. doi: 10.1016/S1470-2045(21)00721-X.
    note
    Source null
    related pmid
    35074073
    relationship
    Comment in

Authors and identifiers

  1. name
    Wang ML
    type
    Author
  2. name
    Jain P
    type
    Author
  3. name
    Zhao S
    type
    Author
  4. name
    Lee HJ
    type
    Author
  5. name
    Nastoupil L
    type
    Author
  6. name
    Fayad L
    type
    Author
  7. name
    Ok CY
    type
    Author
  8. name
    Kanagal-Shamanna R
    type
    Author
  9. name
    Hill HA
    type
    Author
  10. name
    Yao Y
    type
    Author
  11. name
    Hagemeister FB
    type
    Author
  12. name
    Westin JR
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Wang ML
    type
    Author
  2. name
    Jain P
    type
    Author
  3. name
    Zhao S
    type
    Author
  4. name
    Lee HJ
    type
    Author
  5. name
    Nastoupil L
    type
    Author
  6. name
    Fayad L
    type
    Author
  7. name
    Ok CY
    type
    Author
  8. name
    Kanagal-Shamanna R
    type
    Author
  9. name
    Hill HA
    type
    Author
  10. name
    Yao Y
    type
    Author
  11. name
    Hagemeister FB
    type
    Author
  12. name
    Westin JR
    type
    Author
bibliography ids
  1. nci-bib-c2a8a7dff6bf96c37ff6bd6d
book metadata
content sha256
66587f6e13166e6f8f52cdfd2e9f07b6ebdd21507ab172309047de23c5f2220e
document type
citation
dois
  1. 10.1016/S1470-2045(21)00638-0
electronic publication date
display
2022 Jan 21
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35074072
immutable id
pubmed:35074072@66587f6e13166e6f8f52cdfd2e9f07b6ebdd21507ab172309047de23c5f2220e
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
3
name
The Lancet. Oncology
nlm unique id
100957246
pages
406-415
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Mar;23(3):321-322. doi: 10.1016/S1470-2045(21)00721-X.
    note
    Source null
    related pmid
    35074073
    relationship
    Comment in
outcomes validated
false
pmid
35074072
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
6c2a8ece45ab96133a527cac7db57dea7474e8b8c3712e98700e739a68126720
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Mar
precision
month
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Research Support, N.I.H., Extramural
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35074072/
title
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

Preserved source evidence · Not medical advice